Literature DB >> 23015022

Topiramate maculopathy.

William Gualtieri1, Jan Janula.   

Abstract

UNLABELLED: The purpose of this study is to present the first case of a pure 'topiramate maculopathy' without acute glaucoma and/or myopia, which form the classical syndrome.
DESIGN: Interventional/observational case report.
SETTING: Institutional University Teaching Hospital. PATIENT: A 22-year-old American female, after taking 100 mg of topiramate (Topamax®) a day for 6 days because of a migraine attack, complained of severe visual acuity deterioration of sudden onset in both eyes, regardless of distance (far or near), during the span of 1 day. A complete ocular examination was carried out. Best-corrected visual acuity (BCVA) in the right eye was hand motion and in the left eye was counting fingers. Cycloplegic refraction and pinhole did not improve the visual acuity of patient's eyes. The anterior chamber depth was normal in both eyes. Tonometry was 14 mmHg in both eyes. Fundus biomicroscopy disclosed a maculopathy with macular striae and a cellophane-like reflex. Optical coherence tomography (OCT) showed an undulating profile with congruent retinal folds and choroidal layers plicae. INTERVENTIONAL/OBSERVATION PROCEDURE: Immediate discontinuation of Topamax and steroid therapy. MAIN OUTCOME MEASURES: BCVA, cycloplegic refraction, tonometry, fundus photography, and OCT. Three days after suspension of Topomax and steroid therapy the patient's BCVA was 6/6 in both eyes. Tonometry was 14 mmHg in both eyes. Fundus appearance and OCT features were nearly normal. After 2 years of follow-up, the patient's BCVA, tonometry, macula, and OCT are stable in both eyes. In conclusion, an isolated (unassociated with glaucoma and/or induced myopia) acute maculopathy, previously known as being part of a rare syndrome, has been identified, described, and documented.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23015022     DOI: 10.1007/s10792-012-9640-3

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  12 in total

1.  Case reports and small case series: topiramate-induced acute myopia and retinal striae.

Authors:  H A Sen; H S O'Halloran; W B Lee
Journal:  Arch Ophthalmol       Date:  2001-05

2.  Presumed topiramate-induced bilateral acute angle-closure glaucoma.

Authors:  J T Banta; K Hoffman; D L Budenz; E Ceballos; D S Greenfield
Journal:  Am J Ophthalmol       Date:  2001-07       Impact factor: 5.258

3.  Ocular changes associated with topiramate.

Authors:  Banu Turgut Ozturk; Emine Genc; Mine Tokgoz; Hurkan Kerimoglu; Bulent Oguz Genc
Journal:  Curr Eye Res       Date:  2011-01       Impact factor: 2.424

4.  Presumed topiramate-induced maculopathy.

Authors:  Stefan Beyenburg; Christophe Weyland; Markus Reuber
Journal:  Epilepsy Behav       Date:  2009-01-14       Impact factor: 2.937

5.  [Severe ocular side effects with Topamax].

Authors:  V M Asensio-Sánchez; B Torreblanca-Agüera; S Martínez-Calvo; M J Calvo; R Rodríguez
Journal:  Arch Soc Esp Oftalmol       Date:  2006-06

Review 6.  Drug-induced acute angle closure glaucoma.

Authors:  Yves Lachkar; Walid Bouassida
Journal:  Curr Opin Ophthalmol       Date:  2007-03       Impact factor: 3.761

Review 7.  Review of sulfonamide-induced acute myopia and acute bilateral angle-closure glaucoma.

Authors:  Vasudha A Panday; Douglas J Rhee
Journal:  Compr Ophthalmol Update       Date:  2007 Sep-Oct

8.  Electronegative electroretinogram associated with topiramate toxicity and vitelliform maculopathy.

Authors:  Irena Tsui; Daniel Casper; Chai Lin Chou; Stephen H Tsang
Journal:  Doc Ophthalmol       Date:  2007-10-03       Impact factor: 2.379

9.  Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds.

Authors:  B E Maryanoff; S O Nortey; J F Gardocki; R P Shank; S P Dodgson
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

10.  Macular folds: an unusual association in topiramate toxicity.

Authors:  Mukesh Kumar; Siddharth Kesarwani; Aparna Rao; Anshuman Garnaik
Journal:  Clin Exp Optom       Date:  2012-05-09       Impact factor: 2.742

View more
  4 in total

1.  Topiramate maculopathy secondary to dose titration: first reported case.

Authors:  P S Severn; R Symes; R Rajendram; B Pal
Journal:  Eye (Lond)       Date:  2015-05-01       Impact factor: 3.775

2.  Topiramate-induced maculopathy in IgG4-related disease.

Authors:  Joanna DaCosta; Saad Younis
Journal:  Drug Healthc Patient Saf       Date:  2016-06-08

3.  Acute Myopic Shift and Internal Limiting Membrane Folds Linked to Topiramate Use: A Case Report.

Authors:  Levent Dogan
Journal:  Beyoglu Eye J       Date:  2022-02-18

Review 4.  The Ophthalmic Side Effects of Topiramate: A Review.

Authors:  Monia Mechrgui; Suleman Kanani
Journal:  Cureus       Date:  2022-08-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.